© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
April 26, 2021
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
December 15, 2020
Tirbanibulin (Klisyri; Almirall) is indicated for the topical treatment of actinic keratosis on the face or scalp.
October 16, 2020
Clascoterone cream 1% is a first-in-class topical acne treatment that targets the androgen receptors in the skin.
September 03, 2020
Study suggests higher hospitalization rate for some skin diseases.
May 26, 2020
Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.
May 08, 2020
Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.
March 24, 2020
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
March 23, 2020
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.